Andrew Fellowes

Andrew Fellowes

Auto-generated profile, based on publicly available information

Andrew Fellowes

Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2014 in BMC Medical Genomics
Verified
Journal Article
Open access
PDF file
SWStephen Q Wong
Stephen Q Wong
Jason LiJason Li
Jason Li
ATAngela Y-C Tan
Angela Y-C Tan
RVRavikiran Vedururu
Ravikiran Vedururu
JPJia-Min B Pang
Jia-Min B Pang
ADAlexander Dobrovic
Alexander Dobrovic
Clinical specimens undergoing diagnostic molecular pathology testing are fixed in formalin due to the necessity for detailed morphological assessment. However, formalin fixation can cause major issues with molecular testing, as it causes DNA damage such as fragmentation and non-reproducible sequencing artefacts after PCR amplification. In the context of massively parallel sequencing (MPS), distinguishing true low frequency variants from sequencing artefacts remains challenging. The prevalence of formalin-induced DNA damage and its impact on molecular testing and clinical genomics remains poorly understood. The Cancer 2015 study is a population-based cancer cohort used to assess the feasibility of mutational screening using MPS in cancer patients from Victoria, Australia. While blocks were formalin-fixed and paraffin-embedded in different anatomical pathology laboratories, they were centrally extracted for DNA utilising the same protocol, and run through the same MPS platform (Illumina TruSeq Amplicon Cancer Panel). The sequencing artefacts in the 1-10% and the 10-25% allele frequency ranges were assessed in 488 formalin-fixed tumours from the pilot phase of the Cancer 2015 cohort. All blocks were less than 2.5 years of age (mean 93 days). Consistent with the signature of DNA damage due to formalin fixation, many formalin-fixed samples displayed disproportionate levels of C>T/G>A changes in the 1-10% allele frequency range. Artefacts were less apparent in the 10-25% allele frequency range. Significantly, changes were inversely correlated with coverage indicating high levels of sequencing artefacts were associated with samples with low amounts of available amplifiable template due to fragmentation. The degree of fragmentation and sequencing artefacts differed between blocks sourced from different anatomical pathology laboratories. In a limited validation of potentially actionable low frequency mutations, a NRAS G12D mutation in a melanoma was shown to be a false positive. These findings indicate that DNA damage following formalin fixation remains a major challenge in laboratories working with MPS. Methodologies that assess, minimise or remove formalin-induced DNA damaged templates as part of MPS protocols will aid in the interpretation of genomic results leading to better patient outcomes.

20 May 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
RRRichard J. Rebello
Richard J. Rebello
APAtara Posner
Atara Posner
RDRuining Dong
Ruining Dong
OPOwen W. J. Prall
Owen W. J. Prall
TSTharani Sivakumaran
Tharani Sivakumaran
RTRichard W. Tothill
Richard W. Tothill
Genomics can inform both tissue-of-origin (TOO) and precision treatments for patients with cancer of unknown primary (CUP). Here, we use whole genome and transcriptome sequencing (WGTS) for 72 patients and show diagnostic superiority of WGTS over panel testing (386–523 genes) in 71 paired cases. WGTS detects all reportable DNA features found by panel as well as additional mutations of diagnostic or therapeutic relevance in 76% of cases. Curated WGTS features and a CUP prediction algorithm (CUPPA) trained on WGTS data of known cancer types informs TOO in 71% of cases otherwise undiagnosed by clinicopathology review. WGTS informs treatments for 79% of patients, compared to 59% by panel testing. Finally, WGS of cell-free DNA (cfDNA) from patients with a high cfDNA tumour fraction (>7%), enables high-likelihood CUPPA predictions in 41% of cases. WGTS is therefore superior to panel testing, broadens treatment options, and is feasible using routine pathology samples and cfDNA.

1 November 2021 in JCO Precision Oncology
Verified
Journal Article
Closed access
AMAngela Mweempwa
Angela Mweempwa
HXHuiling Xu
Huiling Xu
JVJoseph Henricus Alexander Vissers
Joseph Henricus Alexander Vissers
RTRichard W. Tothill
Richard W. Tothill
APAndrew D. Pattison
Andrew D. Pattison
BSBenjamin J. Solomon
Benjamin J. Solomon

24 May 2023 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
AMArielle van Mourik
Arielle van Mourik
GTGina Tonkin-Hill
Gina Tonkin-Hill
JOJohn O’fArrell
John O’fArrell
SWShohei Waller
Shohei Waller
LTLavinia Tan
Lavinia Tan
LMLinda Mileshkin
Linda Mileshkin
Background: Diagnosis and management of cancers of unknown primary (CUP) remain challenging. This study examines the referral patterns, management and outcomes of patients referred to Australia’s first dedicated CUP clinic. Methods: Retrospective medical record review was conducted for patients seen at the Peter MacCallum Cancer Centre CUP clinic between July 2014 and August 2020. Overall survival (OS) was analysed for patients with a CUP diagnosis where treatment information was available. Results: Of 361 patients referred, fewer than half had completed diagnostic work-up at the time of referral. A diagnosis of CUP was established in 137 (38%), malignancy other than CUP in 177 (49%) and benign pathology in 36 (10%) patients. Genomic testing was successfully completed in 62% of patients with initial provisional CUP and impacted management in 32% by identifying a tissue of origin or actionable genomic alteration. The use of site-specific, targeted therapy or immunotherapy was independently associated with longer OS compared to empirical chemotherapy. Conclusion: Our specialised CUP clinic facilitated diagnostic work-up among patients with suspected malignancy and provided access to genomic testing and clinical trials for patients with a CUP diagnosis, all of which are important to improve outcomes in this patient population.

13 August 1999 in Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology
Verified
Journal Article
Closed access
SBStephen Brennan
Stephen Brennan
AFAndrew P Fellowes
Andrew P Fellowes
PGPeter M George
Peter M George

14 February 2022 in Pathology
Verified
Journal Article
Closed access
JRJames A. Rickard
James A. Rickard
MBMarian L. Burr
Marian L. Burr
BWBernadette Williams
Bernadette Williams
AMAnand Murugasu
Anand Murugasu
AFAndrew Fellowes
Andrew Fellowes
MCMichael Christie
Michael Christie